A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

Inclusion Criteria

• •Participants must be 18 years or older at the time of signing the informed consent.
• •Darolutamide-naïve participants who are with localized prostate adenocarcinoma who plan to receive radical prostatectomy (RP) and defined as high risk with National Comprehensive Cancer Network (NCCN) criteria (version 1.2025).
• •No evidence of distant metastasis based on computed tomography (CT), magnetic resonance imaging (MRI), and whole body bone scan (WBBS) within 42 days prior to start of study treatment.
• •Candidate for RP with pelvic lymph node dissection (PLND) or extended PLND (ePLND) as per the investigator.
• •Participants must have at least one of the following features according to NCCN definition of high-risk:
• •* Biopsy Gleason score ≥8, and/or
• •* Prostate-specific antigen (PSA) \>20 ng/mL measured during Screening and prior to randomization, or
• •* Clinical stage ≥ T3a.
• •Participants with pelvic lymph node involvement (N1) can be included.
• •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.